Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Amal Abu Sabaa,1,2,* Charlott Mörth,3,4 Sverker Hasselblom,2 Gustaf Hedström,2 Max Flogegard,5 Mimmi Stern,6 Per-Ola Andersson,6 Ingrid Glimelius7,2 and Gunilla Enblad2

1Centre for Research and Development, Uppsala University/Region Gavleborg, 2Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, 3Centre for Clinical Research Sormland, Uppsala University, Uppsala, 4Department of Research, Development and Education, Region Halland, Halmstad, 5Department of Internal Medicine, Falun General Hospital, Falun, and 6Department of Hematology, South Alvsborg Hospital, Boras and Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in Europe constituting 30–58% of all lymphoma series.1,2 It is the commonest lymphoma in Sweden with almost 700 cases/year.3 The standard therapy for DLBCL remains anthracycline-based chemotherapy CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOEP (CHOP plus etoposide) in addition to the monoclonal antibody rituximab. In elderly patients, the addition of rituximab to chemotherapy improves the 10-year overall progression-free survival (PFS) and overall survival (OS) by >16%.4 The beneficial effect of rituximab was also confirmed for younger patients with good prognostic factors.5 However, more than one-third of the patients eventually relapse or progress.6,7 Well-established risk factor-based group classification, such as the International Prognostic Index (IPI) and Age Adjusted IPI (aaIPI) and Revised IPI...
(R-IPI), have been used historically to predict OS or PFS. Standard follow-up after completed treatment has routinely been around 5 years. Newer personalised risk prediction models for event-free survival (EFS) at 24 months (EFS24) have emerged and there is increasing evidence that 24 months is a sufficient end-point for follow-up. Maurer et al. reported that patients achieving EFS24 had similar survival as an age- and sex-matched population in the USA and those results were confirmed in a second cohort from France. Interestingly, when looking at the EFS at 12 months (EFS12) milestone poor pretreatment prognostic markers continued to affect survival and prognosis for patients with lymphoma, until they reached EFS24, with the exclusion of Stage I and II. This early stage group had a survival that matched an age- and sex-matched population just after 12 months regardless of pretreatment prognostic factors. In a later study, Maurer et al. concluded that the OS of patients achieving EFS24 was marginally lower, but very similar clinically to an age- and sex-matched population in respective countries in a large multicentre international study up to 7 years after achieving that milestone. However, patient inclusion was largely from clinical trial databases and might therefore not reflect real-life DLBCL patient groups as elderly patients and those with comorbidities were excluded. A later Danish population-based study highlighted that only patients aged <50 years achieving EFS24 had similar OS as the age- and sex-matched Danish standard population. Another publication from British Columbia contradicted the aforementioned findings by showing that there was increased risk of death at EFS24 for patients with DLBCL when compared to age- and sex-matched population regardless of age, Stage and IPI risk. Because of the above-mentioned conflicting results, we aimed to confirm whether EFS24 is a robust outcome in an unselected population of patients with DLBCL compared to age- and sex-matched individuals from the Swedish population. Furthermore, we aimed to explore if other clinical variables influenced the achievement of EFS24. We also evaluated EFS12 as a possible outcome predictor for patients with low-stage DLBCL (Stages I and II). We looked at causes of death, mainly if it was lymphoma related or not. Cardiovascular mortality and secondary malignancies were also of special interest, primarily when evaluating the need for follow-up beyond 2 years.

**Patients and methods**

**Study design and setting**

In this retrospective, multi-institutional cohort study patients were included from the Swedish Lymphoma Registry (SLR). Inclusion was from five Swedish counties; Uppsala, West Gotaland, Gavleborg, Sodermanland and Dalarna. Patients from West Gotaland were diagnosed between the years 2004–2012, whereas patients from the other counties were diagnosed between the years 2001–2014. All patients had DLBCL or high-grade malignant B-cell lymphoma and were treated with rituximab (R)-CHOP or R-CHOP-like regimens with curative intent, i.e. patients treated with less intensive chemotherapy regimens and those who did not receive anthracycline were excluded. Data were collected until November 2018.

**Patient population**

In total, 1169 adult patients (aged ≥18 years) were included. Clinical information was both obtained from the SLR and the patients’ medical records. Patients with primary central nervous system lymphoma, post-transplant lymphoproliferative disorder and human immunodeficiency virus-positive patients were excluded. However, patients with Burkitt-like DLBCL, mediastinal B-cell lymphoma and discordant lymphomas were included, as were transformed indolent lymphomas provided the indolent lymphoma was untreated. The original pathological diagnosis was not re-evaluated. Patients were followed according to the now outdated Swedish Lymphoma Group guidelines with physical examination and laboratory tests every 3–4 months for the first 2 years, at 6 months for year 3 and annually for years 4 and 5.

Recorded baseline data included: age at diagnosis, sex, Eastern Cooperative Oncology Group Performance Status (ECOG PS 0–4), Stage at diagnosis (Ann Arbor I–IV), IPI score, lactate dehydrogenase (LDH; above upper limit normal vs. normal), presence of bulky disease, presence of disease in ≥1 extra-nodal organ, and type of treatment (R-CHOP or R-CHOP*E*) and treatment outcome at the end of treatment (complete response, partial response, stable disease or progressive disease), defined according to International Response Criteria (≥1 extra-nodal organ, and type of treatment). Applicable dates of relapse/death, cause of death (determined by information in medical records or from death certificates) and the date of last follow-up were obtained. Death during treatment or because of relapse was coded as death due to lymphoma. When death was not due to lymphoma, the causes were grouped into cardiovascular disease, cancer, dementia, others and unclear.

Treatment result was evaluated at 6–8 weeks after therapy termination with computed tomography (CT) in all cases and in some of the cases positron-emission tomography (PET). A partial response was considered as unconfirmed complete response in the analysis, provided the patient did not receive additional therapy. The EFS was estimated from the time of diagnosis to the time of relapse or death. Patients in complete remission (CR) and unconfirmed complete remission (CRu) at end of treatment were included in the EFS group. Patients who died before reaching the aforementioned milestones (EFS24, EFS12 for early stage lymphoma) were excluded from the analysis. The OS was defined as time from date of diagnosis until date of death or last follow-up.

Reference age- and sex-matched population. Swedish life tables from Statistics Sweden (www.scb.se) state the historical
individual risk of death depending on sex and age per calendar year. A standard population was generated that matched the study population in terms of age and sex. For each individual, probabilities matched on sex, age and index year for each subsequent year was calculated into a cumulative product of a time-series of likely survival for each individual. Subsequently, the survival of the standard population was compared to the survival of the study population.

Statistical methods

Categorical variables were expressed as number (%) and continuous variables as median (range).

The chi-square test was used for bivariate comparisons of categorical variables. Survival curves with 95% confidence intervals (CIs) were computed using the Kaplan–Meier method. In accordance to statistical methodology no CI was calculated (including only patients achieving the specified milestone in the analysis). A standardised mortality ratio (SMR) was used for multivariate analysis including observed to expected deaths was calculated for 1 and 5 years after achieving the landmark time-point. Cox proportional hazard was used for multivariate analysis including ECOG PS, sex, stage, and treatment regimen.

Results

In this study group of 1169 patients, the median (range) follow-up was 82.3 (0.4–213) months. The median (range) age was 64.6 (18–91) years and 56.6% were men. The ECOG PS was 1–2 in 48.5%. The IPI score was 3–5 in 44.2% and 58.2% had Stage III–IV. Bulky disease was detected in 23.9%. LDH was elevated in 61.7%. Extra-nodal disease was found in 46.4%. Most of the patients (88.5%) received R-CHOP (Table I).

More than two-thirds of the patients (n = 837, 71.6%) achieved EFS24 with better OS compared with those who did not (Fig 1A).

The patients not achieving EFS24 (n = 332, 28.4%) were older (67.6 vs. 63.4 years, P = 0.003), tended to have higher IPI scores (3–5) (62% vs. 34.2%, P < 0.001) and were more likely to have B symptoms (56.6% vs. 38.6%, P < 0.001), bulky disease (31.9% vs. 20.7%, P < 0.001) and extra-nodal involvement (55.7% vs. 42.9%, P < 0.001). There were no significant differences in sex, treatment regimen (R-CHOP vs. R-CHOEP) or the addition of radiotherapy (RT) after R-CHOP treatment between patients achieving EFS24 and those who did not (Table SI).

The OS for all patients with DLBCL was statistically only marginally worse when compared with an age- and sex-matched standard population once EFS24 was reached (Fig 1B): the SMR at 5 years after EFS24 was 1.23 (95% CI 1.02–1.44).

When dividing the study cohort according to age (< or >60 years), we found that patients aged <60 years (n = 266) had an OS comparable to the standard population with only nine events occurring up to 5 years after achievement of the EFS24 milestone (Fig 2A, Table SIIIA); the SMR at 5 years was 2.00 (95% CI 0.70–3.27). However, in patients aged >60 years (n = 571) there were 110 events at 5 years after EFS24 and OS was worse when compared to the standard population (Fig 2B, Table SIIIB), although statistically not significant: SMR 1.19 (95% CI 0.99–1.39).

Table I. Demographic and clinical characteristics.

| Characteristic (N = 1169) | Value | Missing data |
|---------------------------|-------|--------------|
| Age, years, mean (range)  | 64.6  | (18–91)      |
| Age groups, years, n (%)  |       |              |
| <29                       | 22 (1) |              |
| 30–39                     | 49 (4) |              |
| 40–49                     | 89 (7) |              |
| 50–59                     | 179 (15) |            |
| 60–69                     | 361 (30) |             |
| 70–79                     | 333 (29) |             |
| ≥80                       | 136 (11) |            |
| Sex, n (%)                |       |              |
| Male                      | 662 (56) |            |
| Female                    | 507 (43) |            |
| ECOG PS, n (%)            | 17 (1-5) |            |
| 0                         | 485 (41) |            |
| 1–2                       | 572 (48) |            |
| 3–5                       | 89 (7)  |              |
| Stage, n (%)              | 23 (2) |              |
| Stage I–II                | 489 (41) |            |
| Stage III–IV              | 680 (58) |            |
| B symptoms, n (%)         | 511 (43) |            |
| High LDH, n (%)           | 721 (61) |            |
| Bulky, n (%)              | 279 (23) |            |
| Extra-nodal disease, n (%)| 543 (46) |            |
| IPI score, n (%)          | 17 (1-5) |            |
| 0                         | 91 (7)  |              |
| 1–2                       | 544 (46) |            |
| 3–5                       | 517 (44) |            |
| Chemotherapy, n (%)       | 152 (13) |            |
| CHOP                      | 1034 (88) |           |
| CHOP (CHOEP)              | 113 (11) |            |
| Other                     | 4 (0)   |              |
| Radiation therapy, n (%)  | 9 (0-8) |              |

ECOG PS: Eastern Cooperative Oncology Group Performance Status. Extra-nodal disease: involvement of extra-nodal organ. IPI: International Prognostic Index. LDH: lactate dehydrogenase.
Age-stratified analysis demonstrated that in the younger patients groups <29, 30–39, 40–49 and 50–59 years, OS matched that of their peers in the standard population (Fig 1A–D). The OS for patients in the age interval 60–69 years was worse compared to the standard population with a SMR of 1.23 (95% CI 1.02–1.44). Although statistically not significant, the OS for patients aged 70–79 years matched that of their peers without statistical significance, with a SMR of 0.96 (95% CI 0.66–1.21) (Fig S1E–G).

Multivariate Cox regression analyses for patients achieving EFS24 considering risk factors identified by the IPI score,

Fig 1. (A) Overall survival (OS) for patients with diffuse large B-cell lymphoma (DLBCL) who achieved event-free survival at 24 months (EFS24) versus those who did not. Note: Patients with an event prior to 2 years were excluded from the analysis (only applicable for EFS <24 months). (B) OS for patients with DLBCL achieving EFS24 compared with an age- and sex-matched general population. Standardised mortality ratio at 7 years (5 years after relapse-free period) was 1.23 (95% CI 1.02–1.44). [Colour figure can be viewed at wileyonlinelibrary.com]
revealed that an age &gt;60 years and ECOG PS of 4 were the only factors significantly affecting survival when compared to other risk factors after EFS24 (Table SII).

Patients with early stage lymphoma (Stage I–II) achieving EFS12 had a worse OS when compared to the matched standard population (Fig 3B): SMR at 5 years after EFS12 was 1.35 (95% CI 1.07–1.62). However, the OS was better compared with patients not reaching EFS12 (Fig 3A).

Of all 1169 patients, 501 (42.9%) patients died. In the EFS24 group, a total of 190 patients died, with 38 (20%) of the deaths attributed to lymphoma. Causes of death for the remaining 152 patients were as follows: cardiovascular disease...
Discussion
Maurer et al.\textsuperscript{11} showed in two study cohorts that newly diagnosed patients with DLBCL treated with standard immunochemothapy achieving EFS24 and patients with Stage I and II disease who achieved EFS12 had similar OS to the age- and sex-matched standard population. We found in our present unselected patient cohort that this could only be confirmed for patients aged <60 years who achieved EFS24. Furthermore, patients with early stages (I and II) who achieved EFS12 still had a worse
prognosis in comparison to a matched healthy population.

Our present findings with regards to EFS24 resembles the findings of a Danish population-based study where, in a total of 1621 patients, EFS24 was calculated for those with CR or CRu after initial treatment and with a follow-up of ~8 years. They found that only patients aged <50 years had a normalised OS comparable to an age- and sex-matched Danish population, regardless of other risk factors such as IPI score. Interestingly, in a large population-based study from British Columbia (n = 2046) where EFS24 was calculated from diagnosis, the 5-year risk of relapse decreased after achieving EFS24 (33% to 11%), but OS for EFS24 patients remained worse than that of age- and sex-matched local population regardless of age, IPI score and disease stage. However, a pathological subtype analysis showed that patients achieving EFS24 who had either germinal centre B-cell-like or primary mediastinal B-cell lymphoma did have an OS comparable to the standard population. We did not account for histological subtypes in our present analysis.

In 2019, published data from the Netherlands by Van der Galiën et al., supported Maurer’s findings, where patients who achieved PFS24 (319 patients from a total of 585) had an OS that was similar to Maurer’s cohort. The follow-up time was >10 years and PFS24 was calculated from the end of treatment. Of the patients achieving PFS24, only 9% relapsed and 18% died. The causes of death were lymphoma relapse in 19%, cardiovascular in 23%, and other malignancies in 25% of the patients.

The difference in OS for patients achieving EFS24 in the aforementioned studies could be due to the different study populations, but might be also partly due to different definitions of EFS (time from diagnosis vs. time from end of treatment) and in inclusion criteria (patient who achieved CR or CRu).

We also found that established risk factors, e.g. older age, poor ECOG PS at diagnosis, presence of bulky disease, extranodal involvement, high LDH and IPI index, all increased the risk of never reaching EFS24. In part, this has previously been reported in a large study with >7000 patients, which determined the loss of life expectancy and found that mainly IPI score >2 significantly had an impact on the outcome.

Despite the missing causes of death, about one-fifth of the patients achieving EFS24 died from cardiovascular disease. Cardiovascular toxicity secondary to treatment with doxorubicin-based chemotherapy is well described, both early after treatment and as a long-term sequel after non-Hodgkin lymphoma (NHL). The incidence is largely dependent on the cumulative dose. Factors increasing the risk include age, male sex, previous or concurrent mediastinal RT and presence of other cardiovascular risk factors. The classical clinical presentation is congestive cardiac failure, but subclinical left ventricular dysfunction and cardiomyopathy may well precede the onset of symptoms. The risk of cardiac dysfunction in patients aged >50 years receiving a cumulative dose of >200 mg/m² doxorubicin is estimated to be up to 33% within 1 year of treatment. Long-term risk of congestive heart failure is increased in comparison to the normal population. Long-term follow-up of these patients is thus warranted both for clinical assessment and lifestyle counselling with regards to other risk factors, e.g. smoking, obesity, hypertension and hyperlipidaemia. Early intervention should be considered as it may play an important role in reducing cardiac events.

Patients treated for NHL are known to have an increased risk of secondary malignancies such as leukaemia, lung cancer, renal cancer and bladder cancer. Although some studies have shown no difference in the incidence between patients who received RT and those who did not, RT especially in young females is associated with a higher risk of breast cancer. In our present study, 16% of the patients who died without lymphoma, died due to another cancer.

The strengths of the present study include the population-based design, the long duration of follow-up (17-8 years) and the relatively large number of patients with well-documented data. In conclusion, EFS24 appears to be an attractive end-point for follow-up, as most lymphoma-related events occur before this milestone. The Swedish Lymphoma Group considers 2 years of follow-up as satisfactory for relapse-free patients with DLBCL. Yet, this may only be valid for patients aged <60 years. More studies are warranted to understand why. In the meantime, we suggest prolonged follow-up for patients aged >60 years, at least at the primary care level, with regards to a possibly increased risk of cardiovascular disease and secondary malignancies.

Author Contributions

Amal Abu Sabaa: data acquisition, draft of and final approval of manuscript. Charlott Mörtth: data acquisition, draft of and final approval of manuscript. Sverker Hasselblom: data acquisition, manuscript review and final approval of manuscript. Gustaf Hedström: statistical analysis, manuscript draft and final approval of manuscript. Max Floegård: data acquisition and final approval of manuscript. Mimmi Stern: data acquisition. Per-Ola Andersson: data acquisition, manuscript review and final approval of manuscript. Ingrid Glimelius: manuscript review and final approval of manuscript. Gunilla Enblad: data acquisition, manuscript draft and final approval of manuscript.

Conflict of interest

Amal Abu Sabaa, Charlott Mörtth, Sverker Hasselblom, Gustaf Hedström, Max Floegård and Mimmi Stern: none. Per-Ola Andersson: speaker honoraria from Roche, Gilead and Janssen and has been a consultant for Abbvie, Gilead, Janssen and Roche and received an unrestricted research grant from...
Gilead. Ingrid Glimelius: IG honoraria from Janssen and participation in scientific board in a conference organised by Janssen. Gunilla Enblad: speaker honoraria from Roche and Gilead and former member in advisory board for Gilead.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig S1. (A) Overall survival (OS) for patients with diffuse large B-cell lymphoma (DLBCL) aged <29 years who achieved event-free survival at 24 months (EFS24) compared with an age- and sex-matched general population (online only). (B) OS for patients with DLBCL aged 30–39 years who achieved EFS24 compared with an age- and sex-matched general population (online only). (C) OS for patients with DLBCL aged 40–49 years who achieved EFS24 compared with the matched general population. (D) OS for patients aged 50–59 years who achieved EFS24 compared with the matched general population. (E) OS for patients aged 60–69 years who achieved EFS24 compared with the matched general population. (F) OS for patients aged 70–79 years who achieved EFS24 compared with the matched general population. (G) OS for patients age >80 years who achieved EFS24 compared with the matched general population.

Table SII. Demographic and clinical characteristics.

Table SIII. Cox regression for different risk factors according to International Prognostic Index (IPI).

Table SIV. (A) Survival probabilities for overall survival by event-free survival (EFS) ≥24 months and age <60 years compared to the standard population. (B) Survival probabilities for overall survival by EFS ≥24 months and age ≥60 years compared to the standard population.

References

1. Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasia. Hematol Oncol. 2017;35(Suppl 1):37–45.
2. Sant M, Allemani C, Terena C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.
3. Szekely E, Hagberg O, Arrjots K, Jerkeman M. Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study. Leuk Lymphoma. 2014;55:1838–43.
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.
5. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group, Lancet Oncol. 2011;12:1013–22.
6. Sehn LH. A decade of R-CHOP. Blood. 2010;116(12):2000–1.
7. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.
8. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:967–94.
9. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80.
10. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.
11. Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–73.
12. Jakobsen LH, Bogsted M, Brown PN, Arboe B, Jorgensen J, Larsen TS, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol. 2017;35:784–93.
13. Lynch RC, Gratzing D, Advani RH. Clinical impact of the 2016 update to the WHO lymphoma classification. Curr Treat Options Oncol. 2017;18:45.
14. Maurer MJ, Bachy E, Ghesquieres H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096–101.
15. Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29:1822–7.
16. Saur O, Zheng YY, Gerrie AS, Savage KJ, Scott DW, Villa D, et al. EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC). J Clin Oncol. 2016;34(Suppl):7656.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
18. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:779–86.
19. van der Galiën HT, Hoogendoorn M, Kibbelza RE, van Meerten T, van Rijn RS. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting. Ann Oncol. 2019;30:151–2.
20. Ekberg S, Jerkeman M, Andersson PO, Enblad G, Wahlin BE, Hasselblom S, et al. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. Am J Hematol. 2018;93:1020–8.
21. Singal PK, Iltisovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–5.
22. Moser EC, Noordijk EM, van Leeuwen FE, le Cesne S, Baars JW, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107:2912–9.
23. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102–11.
24. Hequet O, Le QH, Mouillet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22:1864–71.
25. Limat S, Demesmay K, Voilat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14:277–81.
26. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomini G, et al. Anthracycline-induced cardiomyopathy: clinical
relevance and response to pharmacologic therapy. *J Am Coll Cardiol.* 2010;55:213–20.
27. Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, et al. Second cancers among long-term survivors of non-Hodgkin’s lymphoma. *J Natl Cancer Inst.* 1993;85:1932–7.
28. Tward JD, Wendland MM, Shrievr DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. *Cancer.* 2006;107:108–15.
29. Boice JD Jr. Radiation and breast carcinogenesis. *Med Pediatr Oncol.* 2001;36:508–13.